Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence
Menée à partir d'échantillons de résection issus de patients atteints d'un cancer de la prostate traité par prostatectomie radicale et à risque intermédiaire de récidive, cette étude met en évidence la possibilité de mesurer, à l'aide d'une IRM 13C hyperpolarisée et d'une analyse métabolomique spatiale, la concentration de lactate au niveau de la tumeur pour identifier les patients présentant un risque de récidive biochimique après l'opération
While radical prostatectomy remains the mainstay of prostate cancer (PCa) treatment, 20 to 40% of patients develop postsurgical biochemical recurrence (BCR). A particularly challenging clinical cohort includes patients with intermediate-risk disease whose risk stratification would benefit from advanced approaches that complement standard-of-care diagnostic tools. Here, we show that imaging tumor lactate using hyperpolarized 13C MRI and spatial metabolomics identifies BCR-positive patients in two prospective intermediate-risk surgical cohorts. Supported by spatially resolved tissue analysis of established glycolytic biomarkers, this study provides the rationale for multicenter trials of tumor metabolic imaging as an auxiliary tool to support PCa treatment decision-making.
Proceedings of the National Academy of Sciences , article en libre accès, 2022